Difficulty: Medium
Average Score: 81%
Testbank
There is a risk of nausea and vomiting from chemotherapy and targeted therapy. Which sets of drugs used for cancer treatment represent a high risk in this regard?
Correct answer
C
Rationale
Carmustine, Cisplatin, and Dacarbazine are known to have a high risk of inducing nausea and vomiting in patients undergoing chemotherapy and targeted therapy.
These drugs are associated with significant emetogenic potential, particularly Cisplatin, which is one of the most potent agents for causing chemotherapy-induced nausea and vomiting (CINV). Carmustine and Dacarbazine also contribute to this risk, making this combination particularly concerning for patients.
A: Butyrophenones, phenothiazines, metoclopramide are primarily antiemetic agents used to manage nausea and vomiting, not chemotherapeutic agents that induce these symptoms, thus not relevant to the stem.
B: Methotrexate, 5-fluorouracil, and doxorubicin can cause nausea, but they are considered to have a moderate emetic risk compared to the high-risk agents listed in option C.
D: The statement incorrectly implies that all chemotherapy will trigger CINV, disregarding the varying emetogenic potentials of different drugs and suggesting a uniformity that does not exist in cancer treatment.
These drugs are associated with significant emetogenic potential, particularly Cisplatin, which is one of the most potent agents for causing chemotherapy-induced nausea and vomiting (CINV). Carmustine and Dacarbazine also contribute to this risk, making this combination particularly concerning for patients.
A: Butyrophenones, phenothiazines, metoclopramide are primarily antiemetic agents used to manage nausea and vomiting, not chemotherapeutic agents that induce these symptoms, thus not relevant to the stem.
B: Methotrexate, 5-fluorouracil, and doxorubicin can cause nausea, but they are considered to have a moderate emetic risk compared to the high-risk agents listed in option C.
D: The statement incorrectly implies that all chemotherapy will trigger CINV, disregarding the varying emetogenic potentials of different drugs and suggesting a uniformity that does not exist in cancer treatment.